Skip to main content

Table 1 Clinical data of 238 nasopharyngeal carcinoma patients

From: Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy

  

Pre-treatment BMI, kg/m2

Variable

All

<23 (N = 81)

≥23 (N = 157)

p

Age, y

50.26 ± 11.82

49.02 ± 12.84

50.09 ± 11.24

0.246

Sex (%)

   

<0.001

 male

169(71.0)

45(55.6)

124(79.0)

 

 female

69(29.0)

36(44.4)

33(21.0)

 

Smoke (%)

   

0.106

 No

160(67.2)

60(74.1)

100(63.7)

 

 Yes

78(32.8)

21(25.9)

57(36.3)

 

CCIS (%)

   

0.742

 0

184(77.3)

64(79.0)

120(76.4)

 

 1

32(13.4)

9(11.1)

23(14.6)

 

 ≥2

22(9.2)

8(9.9)

14(8.9)

 

Histology type

   

0.082

 NUC

214(89.9)

69(85.2)

145(92.4)

 

 NDC

24(10.1)

12(14.8)

12(7.6)

 

T classification (%)

   

0.253

 T1/T2

121(50.8)

37(45.7)

84(53.5)

 

 T3/T4

117(49.2)

44(54.3)

73(46.5)

 

N classification (%)

   

0.779

 N0/N1

62(26.1)

22(27.2)

40(25.5)

 

 N2/N3

176(73.9)

59(72.8)

117(74.5)

 

AJCC Stage (%)

   

0.775

 Stage 1/2

36(15.1)

13(16.0)

23(14.6)

 

 Stage 3/4

202(84.9)

68(84.0)

134(85.4)

 

Treatment arm (%)

   

0.592

 RT alone

41(17.2)

15(18.5)

26(16.6)

 

 CCRT alone

93(39.1)

28(34.6)

65(41.4)

 

 RT/CCRT + CT

104(43.7)

38(46.9)

66(42.0)

 

BWL (%)

   

0.003

 <5 %

88(37.0)

41(50.6)

47(29.9)

 

 ≥5 %

150(63.0)

40(49.4)

110(70.1)

 

Education level (%)

   

0.97

 Low

113(47.5)

39(48.1)

74(47.1)

 

 Medium

70(29.4)

23(28.4)

47(29.9)

 

 High

55(23.1)

19(23.5)

36(22.9)

 

 RT duration

7.46 ± 0.77

7.58 ± 0.80

7.40 ± 0.75

0.091

 Hemoglobin

13.85 ± 1.77

13.28 ± 1.66

14.15 ± 1.75

0.001

  1. CCIS Charlson Comorbidity Index Score; NUC nonkeratinizing undifferentiated carcinoma; NDC nonkeratinizing differentiated carcinoma; BMI body mass index; BWL body weight loss; RT radiotherapy; CT chemotherapy; CCRT concurrent chemoradiotherapy
  2. Values are numbers (percentage)